Combinostics at AAN

April 2-7, 2022  |  Seattle, WA

Will you be attending the 2022 AAN Annual Meeting?

Schedule some time to learn more about how our cNeuro® suite, including the cMRI™ and cDSI™ applications, supports end-to-end management of patients with neurological disorders, from earlier detection to differential diagnosis and monitoring of treatment outcomes.

Using a combination of science and innovative AI technology, we aim to make a difference in the lives of patients with neurological disorders.

Our cNeuro® suite puts the focus on patients by providing clinicians with objective, systematic insights for confident, evidence-based diagnostic and management decisions.

Patient data from multiple sources are integrated and compared with data from previous patients and healthy controls: demographic information, imaging (cMRI) and other biomarkers, clinical characteristics, and neuropsychology tests. 

Applications in the cNeuro® suite:

*WIP – not yet cleared for clinical use.
Play Video
Play Video


Our AI-driven software tools support early detection, differential diagnosis, prediction of progression, and monitoring of neurodegenerative disorders.


cMRI provides fully automated brain MRI quantification for increased throughput, greater objectivity, and high-quality reporting for improved patient care.

Play Video